• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多巴胺D2激动剂S(-)-2-(N-丙基-N-2-噻吩基乙氨基)-5-羟基四氢萘在自由活动大鼠体内的药代动力学

Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats.

作者信息

Swart P J, de Zeeuw R A

机构信息

Department of Analytical Chemistry and Toxicology, University Centre for Pharmacy, Groningen, The Netherlands.

出版信息

J Pharm Sci. 1993 Feb;82(2):200-3. doi: 10.1002/jps.2600820217.

DOI:10.1002/jps.2600820217
PMID:8095299
Abstract

The pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (1, N-0923) after intravenous, intraperitoneal, and oral administration was studied in freely moving male and female albino Wistar rats. In all cases, the dose was 10 mumol.kg-1. Levels of 1 in plasma were monitored up to 6 h after dosing by high-performance liquid chromatography. A biphasic disappearance pattern with a rapid distribution phase was observed in the curve of concentration in plasma versus time. Pharmacokinetic analysis based on a two-compartment model with elimination from the central compartment yielded the following parameters for male rats (mean +/- standard deviation, n = 3): elimination half-life was 108 +/- 7 min, apparent volume of distribution of the central compartment was 397 +/- 44 mL.kg-1, the plasma clearance was 32 +/- 4 mL.min-1.kg-1, and the apparent volume of distribution at steady state was 2.29 +/- 0.25 L.kg-1. No significant difference (analysis of variance p value > 0.25) was found in the pharmacokinetic data between male and female rats. An extremely fast absorption was found after intraperitoneal administration. Maximal concentrations in plasma were often observed at the first time point 5 min after dosing. The bioavailability (mean +/- standard deviation, n = 3) was 7.9 +/- 2.7% for male rats and 6.5 +/- 2.1% for female rats. An increase of the elimination half-life of at least 40% for male rats and 300% for female rats was observed, indicating dose-dependent kinetics after intraperitoneal administration.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在自由活动的雄性和雌性白化Wistar大鼠中,研究了多巴胺D2激动剂S(-)-2-(N-丙基-N-2-噻吩基乙氨基)-5-羟基四氢萘(1,N-0923)静脉注射、腹腔注射和口服给药后的药代动力学。在所有情况下,剂量均为10 μmol·kg-1。通过高效液相色谱法监测给药后6小时内血浆中1的水平。血浆浓度与时间曲线呈现出具有快速分布相的双相消失模式。基于从中央室消除的二室模型进行药代动力学分析,得出雄性大鼠的以下参数(平均值±标准差,n = 3):消除半衰期为108±7分钟,中央室的表观分布容积为397±44 mL·kg-1,血浆清除率为32±4 mL·min-1·kg-1,稳态时的表观分布容积为2.29±0.25 L·kg-1。雄性和雌性大鼠的药代动力学数据之间未发现显著差异(方差分析p值> 0.25)。腹腔注射后发现吸收极快。给药后5分钟的第一个时间点经常观察到血浆中的最大浓度。雄性大鼠的生物利用度(平均值±标准差,n = 3)为7.9±2.7%,雌性大鼠为6.5±2.1%。观察到雄性大鼠的消除半衰期至少增加40%,雌性大鼠增加300%,表明腹腔注射后存在剂量依赖性动力学。(摘要截断于250字)

相似文献

1
Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats.多巴胺D2激动剂S(-)-2-(N-丙基-N-2-噻吩基乙氨基)-5-羟基四氢萘在自由活动大鼠体内的药代动力学
J Pharm Sci. 1993 Feb;82(2):200-3. doi: 10.1002/jps.2600820217.
2
Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats.广泛的胃肠道代谢转化限制了多巴胺D2激动剂N-0923在自由活动大鼠中的口服生物利用度。
Pharmazie. 1992 Aug;47(8):613-5.
3
Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys.食蟹猴中(S)-(-)-2-(N-丙基-N-(2-噻吩基乙基)氨基)-5-羟基四氢萘静脉输注的药代动力学研究
J Pharm Sci. 1994 May;83(5):758-60. doi: 10.1002/jps.2600830533.
4
The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. I. Disposition and metabolic profiling.多巴胺激动剂2-(N-丙基-N-2-噻吩基乙氨基)-5-羟基四氢萘在大鼠静脉注射和口服后的代谢命运。I. 处置与代谢图谱分析。
Xenobiotica. 1990 May;20(5):515-24. doi: 10.3109/00498259009046866.
5
Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in conscious monkeys after subsequent i.v. oral, and ocular administration.多巴胺激动剂2-(N-丙基-N-2-噻吩基乙氨基)-5-羟基四氢萘在清醒猴经静脉、口服和眼部给药后的代谢与处置
Drug Metab Dispos. 1990 Nov-Dec;18(6):923-8.
6
Improvement of the oral bioavailability of the selective dopamine agonist N-0437 in rats: the in vitro and in vivo activity of eight ester prodrugs.
Naunyn Schmiedebergs Arch Pharmacol. 1990 Mar;341(3):186-91. doi: 10.1007/BF00169729.
7
(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0923), a selective D2 dopamine receptor agonist demonstrates the presence of D2 dopamine receptors in the mouse vas deferens but not in the rat vas deferens.(-)-2-(N-丙基-N-2-噻吩基乙氨基)-5-羟基四氢萘(N-0923),一种选择性D2多巴胺受体激动剂,表明在小鼠输精管中存在D2多巴胺受体,而在大鼠输精管中不存在。
J Pharmacol Exp Ther. 1993 Dec;267(3):1342-8.
8
Pharmacological profile of non-hydroxylated and ether derivatives of the potent D2-selective agonist N-0437.强效D2选择性激动剂N-0437的非羟基化和醚衍生物的药理学特性
Naunyn Schmiedebergs Arch Pharmacol. 1991 Feb;343(2):134-42. doi: 10.1007/BF00168600.
9
Direct analysis of the dopamine agonist (-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin hydrochloride in plasma by high-performance liquid chromatography using two-dimensional column switching.使用二维柱切换的高效液相色谱法直接分析血浆中的多巴胺激动剂(-)-2-(N-丙基-N-2-噻吩基乙氨基)-5-羟基四氢萘盐酸盐。
J Chromatogr. 1991 Apr 19;565(1-2):277-95. doi: 10.1016/0378-4347(91)80390-x.
10
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.N-0923是一种选择性多巴胺D2受体激动剂,在帕金森病的大鼠和猴子模型中具有疗效。
Mov Disord. 1994 Mar;9(2):147-54. doi: 10.1002/mds.870090204.

引用本文的文献

1
A liquid crystal in situ gel based on rotigotine for the treatment of Parkinson's disease.基于罗替高汀的液晶原位凝胶治疗帕金森病。
Drug Deliv Transl Res. 2024 Apr;14(4):1048-1062. doi: 10.1007/s13346-023-01449-x. Epub 2023 Oct 24.
2
Skin penetration and mechanisms of action in the delivery of the D2-agonist rotigotine from surfactant-based elastic vesicle formulations.
Pharm Res. 2003 Oct;20(10):1619-25. doi: 10.1023/a:1026191402557.